Incorporating Enzymatic Nanoparticles with the Lateral-Flow Immunoassay for Improved Diagnostic Capabilities
Skip to main content
eScholarship
Open Access Publications from the University of California

UCLA

UCLA Electronic Theses and Dissertations bannerUCLA

Incorporating Enzymatic Nanoparticles with the Lateral-Flow Immunoassay for Improved Diagnostic Capabilities

Abstract

The COVID-19 pandemic has underscored the global need for widespread testing. While current gold standard diagnostics return accurate results, they require expensive lab equipment making them difficult to use in resource-limited settings where the burden of disease is greatest. The lateral-flow immunoassay (LFA) is suitable for point-of-care diagnosis in resource-limited settings, but it suffers from limited sensitivity and lack of quantitative results.In Chapter 2, we increase the sensitivity of the LFA by developing a 3D printed casing that incorporates the LFA, dehydrated signal enhancements reagents, and a buffer reservoir to detect SARS-CoV-2 N-protein in serum at concentrations as low as 0.1 ng/mL. In Chapter 3, we address the lack of quantitative results by integrating the conventional LFA with the anisotropic etching of gold nanorods (GNRs) to achieve a multicolor, semi-quantitative assay that can be interpreted by the naked eye to determine digoxin concentrations in a serum sample.

Main Content
For improved accessibility of PDF content, download the file to your device.
Current View